News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

NPS Pharmaceuticals, Inc. (NPSP) Release: New Data From REPLACE Study Show Initiation of Bone Remodeling for Natpara®-Treated Patients With Hypoparathyroidism


10/15/2012 10:06:20 AM

BEDMINSTER, N.J.--(BUSINESS WIRE)--NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a biopharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, announced today new findings from the double-blind, placebo-controlled Phase 3 REPLACE study of Natpara® (recombinant human parathyroid hormone (rhPTH [1-84]) that show Natpara initiated bone remodeling as demonstrated by significant increases in bone turnover markers. Investigators also reported results from an eight-week study, known as RELAY, which evaluated lower doses of Natpara in hypoparathyroidism. The findings were presented in a poster session at the Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) in Minneapolis, MN.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES